MPR drug database goes mobile

Share this article:
Prescribing Reference (PRI) announced the mobile launch of its Monthly Prescribing Reference (MPR), a drug database for medical professionals.

Physicians can download MPR on a mobile device for free, or as a PC desktop application. The mobile application is compatible with Blackberry, Palm and Microsoft Mobile, as well as Microsoft PC operating systems. PRI is a division of Haymarket Media.

“The MPR drug information was previously available for all Microsoft platforms,” said Jim Pantaleo, vice president and publisher of the MPR product line. “However, many clinicians own BlackBerry and Palm devices, so we needed to make the MPR drug information available to them too. As the iPhone is dramatically changing the mobile market, we are pleased to say that our iPhone application will be available in the third quarter of this year.”

Users downloading the application before August 1, 2009, will be entered into a drawing for a laptop or smartphone.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...